Hyaluronidase Injections for Oral Microstomia in Systemic Sclerosis and Mixed Connective Tissue Disease

JAMA Dermatol. 2023 Dec 1;159(12):1393-1395. doi: 10.1001/jamadermatol.2023.3893.

Authors

Michelle S Min^{1

2}, Nathaniel Goldman¹, Daniel R Mazori^{1

3}, Lisa N Guo¹, Ruth Ann Vleugels¹, Avery H LaChance¹

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, University of California, Irvine School of Medicine, Irvine.
³ Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.

PMID: 37851438
PMCID: PMC10585489 (available on 2024-10-18)
DOI: 10.1001/jamadermatol.2023.3893

No abstract available

Plain language summary

This case series evaluates hyaluronidase for oral microstomia in a cohort of patients with autoimmune sclerosing disease.

MeSH terms

Humans
Hyaluronoglucosaminidase
Microstomia*
Mixed Connective Tissue Disease*
Scleroderma, Systemic* / complications

Substances

Hyaluronoglucosaminidase